Baxter International Inc. ($BAX) Stock Forecast: Up 5.3% Today

What is Baxter International Inc.?

Baxter International Inc. (BAX) is a global healthcare company that focuses on products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions. The company is known for its medical devices, pharmaceuticals, and biotechnology products.

Why is Baxter International Inc. going up?

BAX stock is up 5.3% on Mar 17, 2026 19:10

• Baxter International's stock experienced a strong bullish movement today, despite recent challenges and uncertainties surrounding the departure of CFO Joel Grade.
• The appointment of Anita Zielinski as the interim CFO may have instilled confidence in investors, signaling continuity and stability in the company's financial leadership.
• Despite hitting a 52-week low recently, the market reacted positively to the company's reiteration of its full-year 2026 financial outlook, potentially indicating optimism about Baxter's future performance.
• The divestment of shares by California Public Employees Retirement System in ON Semiconductor Corporation (not directly related to Baxter) may have indirectly impacted market sentiment, leading investors to shift focus towards Baxter International instead.

BAX Price Chart

BAX Technical Analysis

BAX News

Baxter Appoints Anita Zielinski As Interim CFO

Baxter International announced the departure of CFO Joel Grade, who is leaving for family matters but will act in an advisory capacity until April 30, 2026. Anita Zielinski has been appointed as interim CFO, effective immediately, concurrently maintaining her roles as senior vice president, chief accounting officer, and controller. The company also reiterated its full-year 2026 financial outlook.

https://www.citybiz.co/article/819415/baxter-appoints-anita-zielinski-as-interim-cfo/

ON Semiconductor Corporation $ON Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System significantly cut its stake in ON Semiconductor (NASDAQ:ON) by 20.8% in the third quarter, selling 388,321 shares and now holding 1,478,254 shares valued at $72.9 million. This divestment occurred amidst a $6.0 billion share buyback program approved by ON Semiconductor's Board and a "Hold" consensus analyst rating with an average target price near $64.19. The company reported $0.64 EPS, beating estimates, with revenues of $1.53 billion, down 11.2% year-over-year.

https://www.marketbeat.com/instant-alerts/filing-on-semiconductor-corporation-on-shares-sold-by-california-public-employees-retirement-system-2026-03-17/

BofA Maintains Neutral on Baxter International Inc. (BAX) March 2026

Bank of America Securities maintained a Neutral rating on Baxter International Inc. (BAX) on March 16, 2026, citing near-term uncertainty due to the CFO's departure and the stock testing new lows. The firm did not issue a new price target, implying investors should monitor catalysts rather than make immediate moves. Meyka AI rates BAX with a grade of B, while BAX shares recently hit a 52-week low of $17.26, with little immediate market reaction to BofA's maintained rating.

https://meyka.com/blog/bofa-maintains-neutral-on-baxter-international-inc-bax-march-2026-1703/

Baxter International stock hits 52-week low at $16.99

Baxter International's stock has hit a new 52-week low of $16.99, despite an InvestingPro analysis suggesting it is undervalued. The company, which was unprofitable last year, is forecast to return to profitability in 2026 with an expected EPS of $1.92. Recent challenges include an earnings miss in Q4 2025 and a CFO resignation, though BofA Securities maintains a Neutral rating with a $24.00 price target.

https://www.investing.com/news/company-news/baxter-international-stock-hits-52week-low-at-1699-93CH-4563510

Baxter says CFO Joel Grade is leaving the company

Baxter International CFO Joel Grade is set to leave the company. This announcement was made by Baxter, as reported by Crain's Chicago Business. The article briefly states the departure and the date it was reported.

https://www.chicagobusiness.com/health-care/ccb-baxter-cfo-joel-grade-departing-03162026/

Trending Today

Micron Technology Inc. ($MU) Stock Forecast: Down 5.2% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Down 5.2% Today

Ambarella Inc. ($AMBA) Stock Forecast: Up 5.2% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Down 5.0% Today

Saia Inc. ($SAIA) Stock Forecast: Down 5.2% Today

General Electric Company ($GE) Stock Forecast: Down 5.0% Today

Newell Brands Inc. ($NWL) Stock Forecast: Down 5.6% Today

PPG Industries Inc. ($PPG) Stock Forecast: Down 5.1% Today

BP p.l.c. ($BP) Stock Forecast: Up 5.0% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.2% Today

Baxter International Inc. Price History

13.01.2026 - BAX Stock was up 5.2%

• Q4 2025 earnings call transcript revealed detailed discussions on financial performance and future outlook, suggesting positive prospects that resonated well with investors.
• Despite a net loss reported in the 2025 10-K report, Baxter's focus on streamlining operations through divestitures and core segments may have boosted investor confidence in the company's long-term strategy.
• A downgrade to a hold rating following weak Q4 results and a disappointing FY 2026 guide could have initially affected investor sentiment. However, the subsequent appointment of Michael R. McDonnell to the Board of Directors and strategic efforts for a turnaround likely instilled optimism, leading to the stock's bullish movement today.

03.02.2026 - BAX Stock was down 5.2%

• A reduction in stake by CI Investments Inc. in BlackRock might have prompted investors to reallocate their funds, affecting the market sentiment.
• Smith+Nephew's innovative technologies displayed at the AAOS Annual Meeting could have diverted investor attention away from Baxter International, resulting in decreased demand for BAX shares.
• An expansion by Intuitive in Europe may have shifted focus in the overall healthcare market, especially in the medical devices and biotechnology sectors, potentially diverting interest from Baxter International.
• The projected growth in the hemodialysis therapy market suggests a potential change in investor preferences towards companies in the renal care sector, potentially overshadowing Baxter International's performance for the day.

04.01.2026 - BAX Stock was up 5.2%

• BAX encountered challenges in Q4, such as disappointing Q3 results, a dividend reduction, and delays in IV fluid volume normalization and Novum pump shipments, resulting in underperformance.
• Growth projections in the outpatient oncology infusion market could have a beneficial impact on BAX, given its role in fostering innovation in this area.
• Hospitals opting to phase out desflurane over environmental concerns could indirectly assist BAX, as the transition to eco-friendly alternatives may boost the company's image.
• The announcement of Avidity Biosciences' share distribution and Axogen's recent equity offerings might have positively influenced investor sentiment, contributing to the bullish momentum in BAX's stock.

12.01.2026 - BAX Stock was down 12.7%

• Baxter International Inc. reported a Q4 earnings miss and provided a weak outlook for 2026, leading to a sharp decline in its stock price.
• Despite revenue exceeding estimates, the company's adjusted EPS fell short, and its projected earnings for the upcoming year were below expectations, causing concern among investors.
• The substantial GAAP loss and cautious guidance for 2026 highlighted potential profitability and operational challenges for the company, contributing to the bearish market movement.
• The stock tumbled as much as 14.63% in pre-market trading following the disappointing financial results and outlook, reflecting investors' apprehensions about Baxter's performance in the near future.

12.01.2026 - BAX Stock was down 15.0%

• Baxter International Inc. (BAX) saw its stock price plummet by 13.3% to 14.63% in pre-market trading following the earnings announcement.
• The decline in BAX's stock price can be linked to the fourth-quarter earnings falling below analyst expectations, notably with an adjusted EPS of $0.44 missing projections.
• Furthermore, the company's conservative 2026 forecast, with anticipated flat to 1% sales growth and adjusted EPS below consensus estimates, added to investor worries about Baxter's future.
• Despite introducing a new operating model aimed at streamlining its operations and enhancing performance, Baxter's stock experienced a significant drop, overshadowing the efforts to mitigate the impact of the disappointing earnings and outlook.

18.01.2026 - BAX Stock was up 7.5%

• Baxter International (BAX) has experienced a strong bullish movement, with its stock rising by 4.80%.
• The positive market reaction could be attributed to investors potentially viewing the recent losses and challenges as temporary setbacks, leading to increased confidence in the company's future prospects.
• Despite concerns about earnings volatility and debt, the market seems to be responding positively to Baxter International's recent performance, outperforming its competitors on a strong trading day.
• The bullish movement might also be influenced by the overall positive sentiment in the market, as indicated by modest gains in the S&P 500 and Dow Jones Industrial Average.

18.01.2026 - BAX Stock was up 6.6%

• Baxter International (BAX) saw a strong bullish movement despite financial challenges and negative sentiment from analysts.
• The positive market movement could be attributed to investors potentially viewing the company's low valuation metrics, such as the P/S ratio, as compensatory for concerns about earnings volatility and high debt levels.
• The market might be reacting favorably to Baxter International's resilience in the face of financial hurdles, possibly seeing potential for a turnaround in its earnings recovery narrative.
• Despite the obstacles pointed out by analysts, the bullish trend in Baxter International's stock price suggests that investors are optimistic about the company's future prospects and its ability to navigate through the current challenges.

17.02.2026 - BAX Stock was up 5.3%

• Baxter International's stock experienced a strong bullish movement today, despite recent challenges and uncertainties surrounding the departure of CFO Joel Grade.
• The appointment of Anita Zielinski as the interim CFO may have instilled confidence in investors, signaling continuity and stability in the company's financial leadership.
• Despite hitting a 52-week low recently, the market reacted positively to the company's reiteration of its full-year 2026 financial outlook, potentially indicating optimism about Baxter's future performance.
• The divestment of shares by California Public Employees Retirement System in ON Semiconductor Corporation (not directly related to Baxter) may have indirectly impacted market sentiment, leading investors to shift focus towards Baxter International instead.

21.10.2025 - BAX Stock was up 5.2%

• The multiple class action lawsuits against Baxter International might have initially caused uncertainty and a dip in the stock price.
• However, investors might have regained confidence in the company due to positive developments or reassurances from Baxter International's management.
• This bullish movement could indicate that investors believe the impact of the lawsuits on the company's financials and reputation might be manageable.
• It's possible that some investors see an opportunity in the temporary dip caused by the lawsuits and are now buying the stock at a lower price, contributing to the bullish movement.

15.00.2026 - BAX Stock was up 5.2%

• Baxter International Inc. introduced its Dynamo Series smart stretcher, emphasizing technological innovation in acute care to improve patient safety and hospital workflow efficiency, likely boosting the positive stock movement.
• Despite a decrease in stake by Manning & Napier Advisors LLC, growing interest from other institutional investors and Baxter's focus on connected care solutions may have bolstered market confidence and contributed to the bullish trend.
• Initially trailing behind competitors, Baxter International Inc.'s stock performance saw a shift towards optimism with the launch of the Dynamo Series smart stretcher, influencing the bullish market movement.
• FDA clearance for Medtronic's smart insulin pen app, though unrelated to Baxter, indicates progress in healthcare technology, potentially benefiting companies like Baxter International Inc. through positive market effects.

10.01.2026 - BAX Stock was up 5.3%

• The bullish movement in Baxter International Inc. (BAX) could be attributed to the positive news surrounding the company's commitment to respiratory health for patients, showcasing its dedication to improving patient care and quality of life.
• The downgrades from financial firms may have initially caused some uncertainty in the market, but the strong focus on innovative healthcare solutions and patient support likely reassured investors, leading to the bullish trend.
• The workforce reduction at a plant impacted by Hurricane Helene could have been perceived as a strategic move by Baxter to streamline operations and enhance efficiency, potentially positively impacting the company's bottom line and investor confidence.
• The overall positive sentiment towards Baxter International Inc. (BAX) amid its focus on healthcare innovation and patient support likely contributed to the bullish market movement despite some external challenges and analyst downgrades.

12.10.2025 - BAX Stock was up 5.1%

• Despite the pending class action lawsuits and reminders to shareholders, Baxter International Inc. saw a bullish trend, indicating that investors may have confidence in the company's ability to navigate through legal challenges.
• The market movement could be attributed to positive developments within the company that outweigh the legal uncertainties highlighted in recent discussions.
• Investors might be optimistic about Baxter International's future performance and potential growth prospects in the healthcare industry, leading to increased buying activity and driving the stock price higher.